• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Baxter International Inc.

    2/25/25 4:41:54 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email
    POS AM 1 d753291dposam.htm POS AM POS AM

    As filed with the U.S. Securities and Exchange Commission on February 25, 2025

    Registration No. 333-264528

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 1

    to

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    BAXTER INTERNATIONAL INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   36-0781620
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

     

     

    One Baxter Parkway

    Deerfield, Illinois 60015

    (224) 948-2000

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Joel T. Grade

    Executive Vice President and Chief Financial Officer

    Baxter International Inc.

    One Baxter Parkway

    Deerfield, Illinois 60015

    (224) 948-2000

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    With copies to:

     

    Ellen K. Bradford

    Senior Vice President

    and Corporate Secretary

    Baxter International Inc.

    One Baxter Parkway

    Deerfield, Illinois 60015

    (224) 948-2000

     

    Catherine M. Clarkin

    Ari B. Blaut

    Sullivan & Cromwell LLP

    125 Broad Street

    New York, NY 10004

    (212) 558-4000

     

     

    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above-referenced registration statement.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    Baxter International Inc. (the “Registrant”) is filing this post-effective amendment to amend the registration statement on Form S-3 (Registration No. 333-264528), filed by the Registrant with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2022, and declared effective by the SEC on May 11, 2022 (the “Registration Statement”), registering the offer and sale from time to time of up to $10,000,000,000 of the Registrant’s securities.

    The Registrant has determined that it has obtained well-known seasoned issuer status subsequent to filing the Registration Statement and is now eligible to register its securities under a new registration statement on Form S-3ASR (the “New Registration Statement”). In connection with the Registrant filing the New Registration Statement, all offers and sales of the Registrant’s securities registered pursuant to the Registration Statement are being terminated. Accordingly, pursuant to the undertaking contained in the Registration Statement to remove from registration by means of a post-effective amendment any of the securities which remain unsold at the termination of the offering, the Registrant hereby terminates the Registration Statement in respect of any securities that remain unsold and deregisters all securities that remain unsold under the Registration Statement.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Deerfield, State of Illinois, on February 25, 2025.

     

    BAXTER INTERNATIONAL INC.*
    By:  

    /s/ ELLEN K. BRADFORD

     

    Ellen K. Bradford

     

    Senior Vice President and Corporate Secretary

     

    *

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment to the Registration Statement.

    Get the next $BAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    5/10/2024$40.00Buy → Hold
    TD Cowen
    5/30/2023$45.00Equal-Weight
    Morgan Stanley
    3/29/2023$43.00Neutral
    UBS
    More analyst ratings

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Baxter Declares Quarterly Dividend

      Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on July 1, 2025, to stockholders of record as of May 30, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovat

      5/6/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter Reports First-Quarter 2025 Results

      First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company's previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company's previously issued guidance Baxter increases bottom end of previous range for full-year 2025 adjusted diluted EPS guidance and now expects adjusted diluted EPS of $2.47 to $2.551 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. "Our solid performance in the first quarter of

      5/1/25 7:15:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter to Present at Bank of America Securities 2025 Health Care Conference

      Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:40 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Sunday, November 9, 2025. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years

      4/29/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 18, 2024 - FDA Roundup: October 18, 2024

      For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

      10/18/24 4:16:25 PM ET
      $NVCR
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    Financials

    Live finance-specific insights

    See more
    • Baxter Declares Quarterly Dividend

      Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on July 1, 2025, to stockholders of record as of May 30, 2025. The indicated annual dividend rate is $0.68 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovat

      5/6/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter Reports First-Quarter 2025 Results

      First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company's previously issued guidance1,2 First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0.55, exceeding the company's previously issued guidance Baxter increases bottom end of previous range for full-year 2025 adjusted diluted EPS guidance and now expects adjusted diluted EPS of $2.47 to $2.551 Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. "Our solid performance in the first quarter of

      5/1/25 7:15:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter to Host First-Quarter 2025 Financial Results Conference Call for Investors

      Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2025 financial results on Thursday, May 1, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I763359 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on B

      4/15/25 4:15:00 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman resumed coverage on Baxter with a new price target

      Goldman resumed coverage of Baxter with a rating of Buy and set a new price target of $42.00

      2/26/25 7:01:30 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter upgraded by Argus

      Argus upgraded Baxter from Hold to Buy

      2/24/25 10:10:46 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Barclays resumed coverage on Baxter with a new price target

      Barclays resumed coverage of Baxter with a rating of Overweight and set a new price target of $39.00

      2/20/25 8:18:14 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

      SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

      11/13/24 1:08:27 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

      SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

      2/13/24 5:00:53 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Baxter International Inc.

      SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

      2/13/24 1:08:57 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    SEC Filings

    See more
    • Baxter International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      5/8/25 4:15:37 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Baxter International Inc.

      10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      5/6/25 4:34:41 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

      5/1/25 7:17:51 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wilkes David S. was granted 7,183 shares, increasing direct ownership by 43% to 23,906 units (SEC Form 4)

      4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

      5/8/25 4:29:28 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Director Wendell Amy Mcbride was granted 7,183 shares, increasing direct ownership by 30% to 31,222 units (SEC Form 4)

      4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

      5/8/25 4:28:59 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care
    • Director Smith Cathy R was granted 7,183 shares, increasing direct ownership by 31% to 30,345 units (SEC Form 4)

      4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

      5/8/25 4:28:20 PM ET
      $BAX
      Medical/Dental Instruments
      Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Baxter Appoints Jeffrey A. Craig to Its Board

      Addition of Mr. Craig complements current board expertise with deep financial, broad operational and public company board experience Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter's Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12. "We are excited to welcome Jay to Baxter's board," said José (Joe) E. Almeida, chair, president and CEO. "As a former CEO, CFO, COO and public company auditor, Jay's broad-based busin

      9/9/24 9:00:00 AM ET
      $BAX
      Medical/Dental Instruments
      Health Care